@fidjissimo: CAPABLE gives me a lot of hope. Amazing team, who isn’t afraid to redefine what is now possible when it comes to drug d…
Summary
CAPABLE is an AI-driven lab that can go from drug design to data in 24 hours, starting with short-sleeper peptides. The project aims to turn AI capabilities into human capabilities for drug development.
View Cached Full Text
Cached at: 07/09/26, 09:35 AM
CAPABLE gives me a lot of hope. Amazing team, who isn’t afraid to redefine what is now possible when it comes to drug development. Glad to be supporting them.
Isaak (@isaakfreeman): We built the lab that’s able to go from AI-led drug design to data in 24h.
GPT-8 won’t be bottlenecked by intelligence. It needs a biological compute layer.
This is Capable. We’re turning AI capabilities into human capabilities–starting with short-sleeper peptides.
Similar Articles
@robertnishihara: I learned recently that @onepot_ai can synthesize and deliver custom molecules in 5 days, which is incredibly fast. Nor…
Onepot AI can synthesize and deliver custom molecules in just 5 days by combining robotic synthesis with large-scale ML inference on Anyscale, dramatically accelerating drug discovery.
How AI helps scientists design the next generation of medicines
AI is accelerating biologic drug design by predicting candidate molecules and enabling multi-target therapies, with potential to cut discovery timelines by 50% and target previously undruggable diseases.
@fidjissimo: “Once discovery gets cheap, the hard part is clinical trials and patient data” Couldn’t agree more, and that’s where th…
Commentary arguing that as AI makes drug discovery cheap, clinical trials and patient biology data become the bottleneck, highlighting tech giants like Anthropic and OpenAI moving into AI-driven drug development and biotech acquisitions.
@fidjissimo: While AI gives me a lot of hope to find cures for complex chronic conditions like mine, this potential will only be rea…
Former OpenAI executive Fidji Simo discusses her new startup ChronicleBio, which aims to use AI and a biobank of 3,500 blood samples to find cures for chronic conditions like POTS.
@FinanceYF5: Is AI Really Accelerating Drug Development? According to McKinsey's latest research, some early signs have emerged: The…
McKinsey's latest research indicates that AI is accelerating drug development, with candidate drugs utilizing AI to shorten the discovery phase by 15% to 80%.